MoonLake Immunotherapeutics (MLTX) – Research Analysts’ Recent Ratings Updates

MoonLake Immunotherapeutics (NASDAQ: MLTX) has recently received a number of price target changes and ratings updates:

• 9/23/2024 – MoonLake Immunotherapeutics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 9/12/2024 – MoonLake Immunotherapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $62.00 price target on the stock.
• 9/12/2024 – MoonLake Immunotherapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
• 9/9/2024 – MoonLake Immunotherapeutics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 8/26/2024 – MoonLake Immunotherapeutics was downgraded by analysts at Wolfe Research from an “outperform” rating to a “peer perform” rating.
• 8/8/2024 – MoonLake Immunotherapeutics had its price target lowered by analysts at Needham & Company LLC from $66.00 to $62.00. They now have a “buy” rating on the stock.

MoonLake Immunotherapeutics Price Performance

NASDAQ MLTX traded down $0.66 during trading hours on Wednesday, reaching $53.60. The company’s stock had a trading volume of 33,712 shares, compared to its average volume of 379,954. MoonLake Immunotherapeutics has a 52 week low of $35.11 and a 52 week high of $64.98. The stock has a market cap of $3.42 billion, a P/E ratio of -71.47 and a beta of 1.26. The firm has a fifty day simple moving average of $47.04 and a 200-day simple moving average of $44.85.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.11). During the same period in the prior year, the business posted ($0.23) EPS. On average, research analysts expect that MoonLake Immunotherapeutics will post -1.57 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of MLTX. Quarry LP acquired a new stake in MoonLake Immunotherapeutics during the 4th quarter worth about $51,000. Bellevue Group AG acquired a new stake in MoonLake Immunotherapeutics during the first quarter worth approximately $221,000. DNB Asset Management AS increased its holdings in MoonLake Immunotherapeutics by 29.8% in the second quarter. DNB Asset Management AS now owns 7,372 shares of the company’s stock worth $324,000 after purchasing an additional 1,694 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in MoonLake Immunotherapeutics by 50.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 6,147 shares of the company’s stock valued at $371,000 after buying an additional 2,067 shares during the period. Finally, SG Americas Securities LLC bought a new position in shares of MoonLake Immunotherapeutics during the 1st quarter worth approximately $726,000. Institutional investors and hedge funds own 93.85% of the company’s stock.

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.